Nektar's Rezpeg shows strong phase 2 results for atopic dermatitis and alopecia areata, boosting stock outlook.

Nektar Therapeutics reported positive phase 2 data for Rezpeg in treating atopic dermatitis and alopecia areata, two large markets. Rezpeg's strong safety, infrequent dosing, and potential as a first-line alopecia treatment enhance its market potential. The stock outlook improved with over 80% upside and reduced downside risk after the latest data. Nektar is financially strong with $1.1 billion cash and no near-term risks, possibly strengthened further by a Lilly lawsuit settlement.